

Stock Data

Share Price:	0.37p
Market Cap.:	£7.37m
Shares in issue:	1,991.37m
52 week high/low:	0.95p/0.20p

Company Profile


Sector:	Health Care
Ticker:	APTA
Exchange:	AIM

Activities

Aptamer Group plc ('APTA', 'Aptamer' 'the Group') is a leading provider of custom aptamer selection and development services for a wide range of research, diagnostic and therapeutic applications.

www.aptagroup.com

Share price performance since Admission¹



¹22 December 2021

Source: [LSE](https://www.lse.com)

Past performance is not an indication of future performance.

Turner Pope contact details

Tel: 0203 657 0050
Email: info@turnerpope.com
Web: www.turnerpope.com

Andrew Thacker
Corporate Broking & Sales

Barry Gibb
Research Analyst

TPI acts as broker to Aptamer Group plc.

Attention is drawn to the disclaimers and risk warnings at the end of this document.


Retail clients (as defined by the rules of the FCA) must not rely on this document.

Aptamer Group plc

Aptamer has today issued two separate news releases. One of them covers new data that was released at the 2025 American Society for Gene and Cell Therapy ('ASGCT') Annual Meeting (13 - 17 May 2025) confirming Aptamer's Optimer® delivery vehicle, which was originally developed for liver fibrosis, has also been found to be capable of targeting other similarly diseased organs, including the kidney, skin and heart. These findings substantially increase the molecule's commercial scope, potentially positioning it as a highly adaptable therapeutic delivery system with broad applicability across fibrotic disease. They represent a further important step toward unlocking high value opportunities in areas of significant unmet medical need. The other release details the Group's recent winning of two new fee-for-service ('FFS') development contracts from existing customers, with a combined value of up to £231,000, along with agreement of licensing heads of terms with a global provider of specialty enzymes for developed enzyme-modulating Optimers. This adds one further licensing opportunity to the ten that were presented with Aptamer's half year results on 11 March 2025.

Targeted RNA therapies - multiple interested parties

Aptamer's ongoing internal development work and its collaboration with AstraZeneca continues to generate compelling data. Optimer®-siRNA conjugates including those supplied by AstraZeneca have already been successfully generated and tested. Testing various siRNA conjugates confirms that the Group's delivery vehicle effectively and selectively produces robust performances across different payloads, each with the anticipated gene silencing effects. Therapeutic potential for diverse treatment strategies in fibrotic liver cells has thus been demonstrated, with nil impact on healthy liver cells indicating the potential for reduced off-target effects in downstream applications. The technology is developed to a stage where animal model testing is needed.



Source: Aptamer, [Corporate Presentation, April 2025](#)

Liver disease is said to be the only major condition where death rates continue to rise globally. With only one licenced treatment for liver fibrosis, significant unmet need remains. Given that the current annual cost of this

medication is an exceptional c.US\$47,000/patient, there is clearly a high market tolerance for such pricey solutions.

Although liver fibrosis will remain a major focus for Aptamer, due to its large market growth rate (24% per annum through to 2035, driven by new drugs under development and rising disease prevalence, according to market forecaster, DelveInsight) and limited treatment options, potential for expansion into pulmonary, renal, cardiac, and dermal fibrosis presents yet further commercial opportunity for the delivery system. Recognising this, and the need for animal model validation, multiple pharmaceutical companies have already initiated discussions with Aptamer to explore possible development partnerships over the next few months.

Licensing with global enzyme provider for two Optimer® reagents in research and diagnostics

The licensing terms with a global enzyme provider cover Optimer® binders developed under two separate FFS contracts. The binders for the first contract were successfully delivered in January 2025 and demonstrated excellent performance both at Aptamer and in the customer's in-house tests, leading to the additional FFS work. The agreed licensing terms for this contract include undisclosed milestone payments and a 10% royalty on sales of all Optimer® containing products. Initial revenues from this non-exclusive arrangement are expected within the next financial year and add one further licensing opportunity to the ten that were presented with the Group's interim results on 11 March 2025. Licensing terms on the second contract will also earn 10% royalties and have additional undisclosed financial terms on the commercialisation of successfully developed Optimers. The provider operates within the global PCR market, which was valued at US\$9.9 billion in 2024 and is currently expanding at a CAGR of 8.6% according to market researcher, Fortune Business Insights.

Repeat FFS development contracts worth up to £231,000 signal continued commercial traction

The first of the two new FFS development contracts, valued at up to £105,000, focuses on creating additional enzyme-modulating Optimers to broaden the customer's reagent offering. This is a second project with this customer. The second development contract is with a top 20 global pharmaceutical company. Valued at up to £126,000, this new FFS project will involve the development of Optimer® reagents targeting a small molecule for use in the customer's internal research programmes. This marks a second project with this particular customer, following a previously successful Optimer® development. Aptamer will retain IP rights on the binders, with potential for future downstream licensing revenue. Such repeat engagements with respected global players, validate the platform's utility and reinforces the Group's strategic focus on long term, sustainable growth.

Aptamer's portfolio of assets moving incrementally closer to a value inflection point(s)

Along with today's important product news, FFS contracts and licensing agreement, recent months have also seen strategic developments with Unilever and Neuro-Bio advancing through key milestones and technological validation, while also achieving a state of final commercial preparedness for another Optimer® delivery vehicle that is being tested with the Group's genetics medicine partner. Taken altogether, this progress continues to enhance Aptamer's portfolio of assets as it moves incrementally closer to a value inflection point(s) with heightening licensing potential. Revenue recognition also continues to increase, supported by a robust pipeline of FFS projects and opportunities as they advance through the Group's laboratories. Such contracts can sometimes take extended periods to negotiate with its lengthening list of customers, primarily because Aptamer insists on securing the best contractual terms and conditions to ensure all agreements capture the best long-term growth potential and prospective licensing returns. Based nevertheless on simply being able to sustain its existing trajectory of incoming FFS work and having completed the scale back of its cost base, the Board continues to project cash-in-hand (incl. annual R&D tax credits) will be sufficient to satisfy working capital needs out to end-June 2026, by which time anticipated first collection of milestone payments, licensing fees and/or royalties offer potential for it to become financially self-sustaining going forward. Although such passive income, which could commence during the current calendar year, is initially likely to be modest, there is scope for it to multiply substantially thereafter. Seemingly unrecognised in the Group's current valuation, any such breakthrough adoption(s) would be transformative for Aptamer, both financially and in terms of reputation.

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as broker to Aptamer Group plc ('Aptamer Group') which is listed on the AIM Market of the London Stock Exchange ('AIM'). TPI's private and institutional clients may hold, subscribe for or buy or sell Aptamer Group's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of Aptamer Group.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2025 Turner Pope Investments (TPI) Limited, all rights reserved.